149 related articles for article (PubMed ID: 36863416)
1. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials.
Smith CP; Xiang M; Armstrong WR; Nickols NG; Steinberg ML; Reiter RE; Rettig M; Weiner AB; Shen J; Valle L; Czernin J; Calais J; Kishan AU
Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1079-1084. PubMed ID: 36863416
[No Abstract] [Full Text] [Related]
2. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA
Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464
[TBL] [Abstract][Full Text] [Related]
3. High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer.
Ptasznik G; Papa N; Kelly BD; Thompson J; Stricker P; Roberts MJ; Hofman MS; Buteau J; Murphy DG; Emmett L; Moon D
BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):5-7. PubMed ID: 35362659
[No Abstract] [Full Text] [Related]
4.
Lopci E; Saita A; Lazzeri M; Lughezzani G; Colombo P; Buffi NM; Hurle R; Marzo K; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Lista G; Cardone P; Castello A; Maffei D; Balzarini L; Chiti A; Guazzoni G; Casale P
J Urol; 2018 Jul; 200(1):95-103. PubMed ID: 29409824
[TBL] [Abstract][Full Text] [Related]
5. How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
Ptasznik G; Kelly BD; Murphy D; Lawrentschuk N; Kasivisvanathan V; Page M; Ong S; Moon D
BJU Int; 2024 Feb; 133 Suppl 3():13-14. PubMed ID: 37691457
[No Abstract] [Full Text] [Related]
6. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
7. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
8. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better?
Varatharajan A; Olivier T; Prasad V
Eur Urol; 2023 Jun; 83(6):481-483. PubMed ID: 36774222
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer.
O'Brien JS; McVey A; Kelly BD; Jenjitranant P; Buteau J; Hofman MS; Kasivisvanithan V; Eapen R; Moon D; Murphy DG; Lawrentschuk N
BJU Int; 2022 Nov; 130 Suppl 3():8-10. PubMed ID: 35574991
[No Abstract] [Full Text] [Related]
11. Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer.
Petersen LJ; Zacho HD
Scand J Urol; 2017 Dec; 51(6):498-501. PubMed ID: 28748722
[No Abstract] [Full Text] [Related]
12. The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography.
Veerman H; Donswijk M; Bekers E; Bodar YJL; Meijer D; van Moorselaar RJA; Oprea-Lager DE; van der Noort V; van Leeuwen PJ; Vis AN; van der Poel HG
BJU Int; 2022 Dec; 130(6):750-753. PubMed ID: 36117468
[No Abstract] [Full Text] [Related]
13. The clinical characteristics of patients with primary non-prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography.
Veerman H; Donswijk M; Bekers E; Olde Heuvel J; Bodar YJL; Boellaard TN; van Montfoort ML; van Moorselaar RJA; Oprea-Lager DE; van Leeuwen PJ; Vis AN; van der Poel HG
BJU Int; 2022 Mar; 129(3):314-317. PubMed ID: 34854204
[No Abstract] [Full Text] [Related]
14. Detection and localisation of primary prostate cancer using
Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
[TBL] [Abstract][Full Text] [Related]
15. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
van Kalmthout LWM; van Melick HHE; Lavalaye J; Meijer RP; Kooistra A; de Klerk JMH; Braat AJAT; Kaldeway HP; de Bruin PC; de Keizer B; Lam MGEH
J Urol; 2020 Mar; 203(3):537-545. PubMed ID: 31487220
[TBL] [Abstract][Full Text] [Related]
16. Confirming and Refining Our Existing Postoperative Treatment Strategies Through the Use of Novel Prostate-Specific Positron Emission Tomography (PET) Imaging.
Hall WA; Lawton CAF
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):118-119. PubMed ID: 36526378
[No Abstract] [Full Text] [Related]
17. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
18. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
[TBL] [Abstract][Full Text] [Related]
19. Research Highlight:
Fütterer JJ; Nagarajah J
Korean J Radiol; 2022 Mar; 23(3):293-294. PubMed ID: 35213092
[No Abstract] [Full Text] [Related]
20. Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.
Rajwa P; Pfister D; Rieger C; Heidenreich J; Drzezga A; Persigehl T; Shariat SF; Heidenreich A
Prostate; 2023 Mar; 83(4):385-391. PubMed ID: 36564936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
